Trevena, Inc. (TRVN)
| Market Cap | 123.39M |
| Revenue (ttm) | 637,000 |
| Net Income (ttm) | -49.51M |
| Shares Out | 164.52M |
| EPS (ttm) | -0.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,949,524 |
| Open | 0.681 |
| Previous Close | 0.680 |
| Day's Range | 0.681 - 0.760 |
| 52-Week Range | 0.630 - 3.100 |
| Beta | 2.23 |
| Analysts | Buy |
| Price Target | 4.67 (+522.7%) |
| Earnings Date | Nov 15, 2021 |
About TRVN
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agon...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for Trevena stock is "Buy." The 12-month stock price forecast is 4.67, which is an increase of 522.67% from the latest price.
News
Trevena (TRVN) Reports Q3 Loss, Lags Revenue Estimates
Trevena (TRVN) delivered earnings and revenue surprises of 11.11% and -84.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Trevena Reports Third Quarter 2021 Results
-- Advanced OLINVYK commercial launch with expanded field medical team and additional target markets
Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team
Patricia Drake appointed new Chief Commercial Officer Patricia Drake appointed new Chief Commercial Officer
Trevena to Release Third Quarter 2021 Financial Results on November 15th, 2021
Company to host conference call on Monday, November 15th, 2021 at 8:00 a.m. ET Company to host conference call on Monday, November 15th, 2021 at 8:00 a.m. ET
Earnings Preview: Trevena (TRVN) Q3 Earnings Expected to Decline
Trevena (TRVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Trevena Announces Two OLINVYK® Presentations at ANESTHESIOLOGY® 2021
Posters highlight safety and tolerability data in two complex patient populations at higher risk for adverse events Posters highlight safety and tolerability data in two complex patient populations at h...
5 Penny Stocks To Watch This Week With Potential Biotech Catalysts
Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Informatio...
Trevena Posts TRV027 Proof-of-Concept Study In Hospitalized COVID-19 Patients
Trevena Inc (NASDAQ: TRVN) has announced data from 30 patients enrolled in the proof-of-concept study of TRV027 in hospitalized COVID-19 patients. The results showed that TRV027 was well-tolerated and ...
Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients
-- 92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical illness and mortality
Trevena to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit
CHESTERBROOK, Pa., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with cent...
Imvax Appoints John M. Limongelli as Chief Legal Officer
PHILADELPHIA--(BUSINESS WIRE)--Imvax announced the appointment of John M. Limongelli as the Company's Chief Legal Officer effective September 16, 2021.
Trevena Announces Two OLINVYK® Abstracts Highlighting Safety Data Accepted at ANESTHESIOLOGY® 2021
CHESTERBROOK, Penn., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with cen...
Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study
-- Study is being led by Cleveland Clinic; designed to evaluate potential benefit of OLINVYK on respiratory, GI, and cognitive function outcomes in postoperative patients
New Strong Sell Stocks for August 20th
ADXN, CSSE, HSDT, LYRA, and TRVN have been added to the Zacks Rank #5 (Strong Sell) List on August 20, 2021.
Trevena (TRVN) Reports Q2 Loss, Misses Revenue Estimates
Trevena (TRVN) delivered earnings and revenue surprises of -12.50% and -85.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Trevena: Q2 Earnings Insights
Shares of Trevena (NASDAQ:TRVN) rose 0.7% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 50.00% over the past year to ($0.09), which missed t...
Trevena Reports Second Quarter 2021 Results
Company reaffirms YE goal of 100 formulary wins
Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy
Exploratory analysis shows OLINVYK treated patients are ~50% less likely to experience an AE compared to morphine patients at equivalent levels of analgesia Exploratory analysis shows OLINVYK treated pa...
Trevena to Release Second Quarter 2021 Financial Results on August 12th, 2021
Company to host conference call on Thursday, August 12th, 2021 at 8:00 a.m. ET Company to host conference call on Thursday, August 12th, 2021 at 8:00 a.m. ET
Trevena Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Trial of TRV027 for COVID-19
TRV027 will be dosed in ~300 patients in nationwide trial led by Vanderbilt University Medical Center (VUMC) TRV027 will be dosed in ~300 patients in nationwide trial led by Vanderbilt University Medica...
Trevena Announces Two Leading Independent Proxy Advisory Firms Recommend Shareholders Vote “For” All Proposals Ahead ...
Glass Lewis and Institutional Shareholder Services (ISS) independently recommend that Trevena shareholders vote “FOR” proposals to approve a Reverse Stock Split and concurrent Authorized Share Reduction...
Trevena Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research
Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care
Trevena Announces First Patient Enrolled in OLINVYK® Phase 3 Trial in China in Partnership with Jiangsu Nhwa Pharmace...
Nhwa is conducting and funding this study to support NDA regulatory filing in China
Trevena Announces Initiation of OLINVYK® Respiratory Physiology Study Including Elderly / Obese Subjects
-- Study is evaluating the role of age and weight in a comparative analysis of the effect of OLINVYK and morphine on respiratory function
All You Need to Know About Trevena (TRVN) Rating Upgrade to Buy
Trevena (TRVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).